Clin Infect Dis, 2022, 75(1):e1-e9

SARS-CoV-2-specific T cells and antibodies in COVID-19 protection: a prospective study

During the ongoing coronavirus disease COVID-19 pandemic, many individuals were infected with and have cleared the virus, developing virus-specific antibodies and effector/memory T cells. An important unanswered question is what levels of T cell and antibody responses are sufficient to protect from the infection.

Molodtsov IA, Kegeles E, Mitin AN, Mityaeva O, Musatova OE, Panova AE, Pashenkov MV, Peshkova IO, Alsalloum A, Asaad W, Budikhina AS, Deryabin AS, Dolzhikova IV, Filimonova IN, Gracheva AN, Ivanova OI, Kizilova A, Komogorova VV, Komova A, Kompantseva NI, Kucheryavykh E, Lagutkin DA, Lomakin YA, Maleeva AV, Maryukhnich EV, Mohammad A, Murugin VV, Murugina NE, Navoikova A, Nikonova MF, Ovchinnikova LA, Panarina Y, Pinegina NV, Potashnikova DM, Romanova EV, Saidova AA, Sakr N, Samoilova AG, Serdyuk Y, Shakirova NT, Sharova NI, Sheetikov SA, Shemetova AF, Shevkova LV, Shpektor AV, Trufanova A, Tvorogova AV, Ukrainskaya VM, Vinokurov AS, Vorobyeva DA, Zornikova KV, Efimov GA, Khaitov MR, Kofiadi IA, Komissarov AA, Logunov DY, Naigovzina NB, Rubtsov YP, Vasilyeva IA, Volchkov P, Vasilieva E

Department of Peptide and Protein Technologies, Laboratory of biocatalysis, Department of functioning of living systems, Laboratory of molecular oncology, Laboratory of molecular virology

: 10.1093/cid/ciac278
Scopus: 2-s2.0-85137124808
: 35435222
IBCH: 9977
Ссылка на статью в журнале: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac278/6567222
Кол-во цитирований на 02.2024: 18
Данные статьи проверены модераторами 2022-05-04

Список научных проектов, где отмечена публикация

  1. DZM-30-3. . Сommercial.
  2. 075-15-2020-899. . Сommercial.
  3. KNP-06/21. . Сommercial.